Bronchogen Peptide (20mg)

$69.97

Bronchogen is a four–amino acid peptide (tetrapeptide) with the sequence alanine–glutamic acid–aspartic acid–leucine (Ala-Glu-Asp-Leu). It is classified as a bioregulatory peptide and has been described as potentially supporting DNA stability, with possible bronchodilatory and anti-inflammatory effects in respiratory system conditions.

Description

Bronchogen Peptide Product Description

Bronchogen is a tetrapeptide made up of four amino acids (Ala-Glu-Asp-Leu) known for its DNA-stabilizing properties and its role as a bioregulator with a focus on lung tissue. It is primarily associated with supporting reduced inflammation in the lungs, enhancing epithelial cell activity, and promoting increased surfactant production.

Bronchogen Peptide Benefits

  • Reduced lung inflammation
    May help modulate inflammatory responses in lung tissue, supporting calmer airway function.
  • Support for epithelial cell function
    Often described as helping maintain or improve the health of the respiratory tract lining (epithelium), which is important for barrier protection and repair.
  • Enhanced surfactant production
    Surfactant helps keep the lungs expanded and improves gas exchange efficiency, so increased production may support easier breathing mechanics.
  • DNA-stabilizing activity (theoretical/bioregulatory claim)
  • General respiratory system support
    Sometimes used in discussions around helping recovery or resilience in lung tissue under stress (environmental irritants, inflammation, etc.).

The Bronchogen Peptide Specifications

Property Value
Peptide Sequence Ala-Glu-Asp-Leu
Molecular Formula C18H30N4O9
Molecular Weight 446.45 g/mol
Synonyms Peptide AEDL

 

Bronchogen Peptide Dosage

It is a bioregulatory research peptide, and most dosing information comes from practitioner protocols, experimental use, or regional peptide literature rather than controlled clinical trials.

That said, commonly circulated informational (non-clinical) usage ranges in peptide communities are:

  • Typical cycle length: ~10–20 days
  • Route: usually subcutaneous injection (in research settings)
  • Frequency: often described as once daily or every other day
  • Cycle repetition: some protocols suggest repeating after a break (commonly 2–4 weeks)

Some sources loosely group Bronchogen with other short bioregulatory tetrapeptides and treat it as a low-dose, short-cycle compound, but exact standardized dosing does not exist.

Cart0
Cart0